I-MAB American Depositary Shares
N/A
USD
N/A
N/A
...
Chart
Financials
Description
IMAB Company Description
I-Mab Biopharma is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
IMAB Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view IMAB Smart Score
Score Breakdown
IMAB Company Description
Show More
I-Mab Biopharma is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B). Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of IMAB by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by IMAB's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of IMAB in WallStreetBets Daily Discussion
IMAB News
Recent insights relating to IMAB
CNBC Recommendations
Recent picks made for IMAB stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in IMAB
Corporate Flights
Flights by private jets registered to IMAB
Our Analysis